TRCT
REPL icon

Tower Research Capital (TRC)’s Replimune Group REPL Stock Holding History

Tower Research Capital (TRC)’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$83.9K Buy
10,968
+7,127
+186% +$54.5K ﹤0.01% 2328
2025
Q4 		$37.3K Sell
3,841
-3,881
-50% -$33K ﹤0.01% 2646
2025
Q3 		$32.4K Sell
7,722
-1,970
-20% -$12.6K ﹤0.01% 2878
2025
Q2 		$90K Buy
9,692
+9,235
+2,021% +$80.6K ﹤0.01% 2467
2025
Q1 		$4.46K Sell
457
-6,315
-93% -$78.1K ﹤0.01% 4253
2024
Q4 		$82K Buy
6,772
+5,922
+697% +$72K ﹤0.01% 2267
2024
Q3 		$9.32K Sell
850
-26,533
-97% -$270K ﹤0.01% 3880
2024
Q2 		$246K Buy
27,383
+24,421
+824% +$170K ﹤0.01% 1911
2024
Q1 		$24.2K Sell
2,962
-1,245
-30% -$10.2K ﹤0.01% 2825
2023
Q4 		$35.5K Buy
4,207
+2,958
+237% +$34.3K ﹤0.01% 3338
2023
Q3 		$21.4K Sell
1,249
-7,441
-86% -$146K ﹤0.01% 3314
2023
Q2 		$202K Buy
8,690
+2,197
+34% +$42.9K 0.01% 1551
2023
Q1 		$115K Buy
6,493
+3,877
+148% +$92.2K ﹤0.01% 1739
2022
Q4 		$72K Sell
2,616
-6,363
-71% -$132K ﹤0.01% 2087
2022
Q3 		$155K Buy
8,979
+213
+2% +$4.06K ﹤0.01% 2166
2022
Q2 		$153K Sell
8,766
-12,729
-59% -$209K ﹤0.01% 1975
2022
Q1 		$365K Buy
21,495
+16,555
+335% +$312K ﹤0.01% 1346
2021
Q4 		$134K Buy
4,940
+2,684
+119% +$80.3K ﹤0.01% 2048
2021
Q3 		$67K Sell
2,256
-3,334
-60% -$108K ﹤0.01% 2726
2021
Q2 		$215K Buy
5,590
+3,493
+167% +$119K 0.01% 1865
2021
Q1 		$64K Buy
2,097
+1,358
+184% +$50.9K ﹤0.01% 2915
2020
Q4 		$29K Sell
739
-17,410
-96% -$725K ﹤0.01% 3603
2020
Q3 		$418K Buy
18,149
+15,061
+488% +$343K ﹤0.01% 1878
2020
Q2 		$77K Buy
3,088
+1,597
+107% +$28.2K ﹤0.01% 2691
2020
Q1 		$15K Buy
+1,491
New +$22.2K ﹤0.01% 1844
2019
Q4 		– Sell
-547
Closed -$8K – 4231
2019
Q3 		$8K Buy
+547
New +$6.71K ﹤0.01% 3089
2019
Q2 		– Sell
-821
Closed -$12K – 4175
2019
Q1 		$12K Sell
821
-2,928
-78% -$36.5K ﹤0.01% 2588
2018
Q4 		$37K Buy
3,749
+1,789
+91% +$24.2K ﹤0.01% 1492
2018
Q3 		$32K Buy
+1,960
New +$34.4K ﹤0.01% 2036

Other funds holding REPL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tower Research Capital (TRC)'s REPL Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Replimune Group (REPL) stake by 186% in Q1 2026, buying an estimated $54.5K and bringing the position to 10,968 shares worth $83.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2328.

Tower Research Capital (TRC) first reported a position in REPL in Q3 2018 and has held it in 29 quarters since. The position peaked at $418K in Q3 2020. 180 funds tracked by Wall St. Rank hold REPL as of Q1 2026.

  • Tower Research Capital (TRC) held 10,968 shares of Replimune Group worth $83.9K as of Q1 2026.
  • Tower Research Capital (TRC) bought 7,127 Replimune Group shares in Q1 2026, an estimated $54.5K.
  • Replimune Group made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2328 holding.
  • Tower Research Capital (TRC) first reported a position in Replimune Group in Q3 2018 and has held it in 29 quarters since.
  • Tower Research Capital (TRC)'s Replimune Group position peaked at $418K in Q3 2020.
  • 180 funds tracked by Wall St. Rank held Replimune Group as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.